Skip to main content

letter

. 1984 Oct;18(4):652–653. doi: 10.1111/j.1365-2125.1984.tb02525.x

Decreased alpha 1-acid glycoprotein in liver cirrhosis: consequences for drug protein binding.

J Barre, G Houin, J Rosenbaum, R Zini, D Dhumeaux, J P Tillement

PMCID: PMC1463634 PMID: 6487513

652

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Austin K. L., Mather L. E., Philpot C. R., McDonald P. J. Intersubject and dose-related variability after intravenous administration of erythromycin. Br J Clin Pharmacol. 1980 Sep;10(3):273–279. doi: 10.1111/j.1365-2125.1980.tb01755.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
Chio L. F., Oon C. J. Changes in serum alpha 1 antitrypsin, alpha1 acid glycoprotein and beta 2 glycoprotein I in patients with malignant hepatocellular carcinoma. Cancer. 1979 Feb;43(2):596–604. doi: 10.1002/1097-0142(197902)43:2<596::aid-cncr2820430229>3.0.co;2-r. [DOI] [PubMed] [Google Scholar]
Piafsky K. M., Borgá O., Odar-Cederlöf I., Johansson C., Sjöqvist F. Increased plasma protein binding of propranolol and chlorpromazine mediated by disease-induced elevations of plasma alpha1 acid glycoprotein. N Engl J Med. 1978 Dec 28;299(26):1435–1439. doi: 10.1056/NEJM197812282992604. [DOI] [PubMed] [Google Scholar]
Piafsky K. M. Disease-induced changes in the plasma binding of basic drugs. Clin Pharmacokinet. 1980 May-Jun;5(3):246–262. doi: 10.2165/00003088-198005030-00004. [DOI] [PubMed] [Google Scholar]
Serbource-Goguel N., Corbic M., Erlinger S., Durand G., Agneray J., Feger J. Measurement of serum alpha 1-acid glycoprotein and alpha 1-antitrypsin desialylation in liver disease. Hepatology. 1983 May-Jun;3(3):356–359. doi: 10.1002/hep.1840030313. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES